What pharmacy technicians say would actually make them feel seen on World Pharmacy Technician Day, and the other 364 days of the year.
|Articles|January 22, 2008
New drug approval addresses two cardiovascular risk factors
Daiichi Sankyo's Welchol, formerly approved to lower LDL-C, has been cleared to reduce blood glucose levels in Type 2 diabetics
Advertisement
Daiichi Sankyo's Welchol (colesevelam HCl) has gained approval for a new indication. It can be used to reduce AIC in adults with Type 2 diabetes. The bile acid sequestrant was approved in 2000 alone or in combination with a statin to reduce elevated LDL-C in patients with primary hypercholesterolemia. The Parsippany, N.J., firm claims the product is the first and only medication approved to lower both glucose levels and low-density lipoprotein cholesterol.
Advertisement
Related to this article
The analysis is not a head-to-head trial, and the weight loss gap reached statistical significance under 1 of 2 estimands.
A 1.6-million-birth analysis finds that adoption of a 2016 trial's antibiotic protocol climbed sharply in US hospitals, with a drop in infection rates.
New findings suggest semaglutide's benefits may extend well beyond diabetes and weight loss and into airway disease and mood disorders.
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.
A claims analysis of 2031 patients aged 10 to 17 years found that nutrition counseling was infrequent and often began months after treatment started.
Community pharmacists offer accessible care, improve medication adherence, and build trust through education, vaccination support, and local health leadership.
Advertisement
Advertisement